300
Participants
Start Date
August 29, 2018
Primary Completion Date
September 7, 2022
Study Completion Date
September 7, 2022
Mepolizumab 100 milligrams
Mepolizumab will be given as a lyophilized cake in sterile vials for individual use. The vial will be reconstituted with Sterile Water for Injection, just prior to use.
Placebo
Placebo will be given as 0.9 percent sodium chloride solution.
Salbutamol
Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
GSK Investigational Site, Beijing
GSK Investigational Site, Beijing
GSK Investigational Site, Beijing
GSK Investigational Site, Shenyang
GSK Investigational Site, Shenyang
GSK Investigational Site, Changchun
GSK Investigational Site, Changchun
GSK Investigational Site, Shanghai
GSK Investigational Site, Shanghai
GSK Investigational Site, Shanghai
GSK Investigational Site, Shanghai
GSK Investigational Site, Shanghai
GSK Investigational Site, Nanjing
GSK Investigational Site, Wuxi
GSK Investigational Site, Suzhou
GSK Investigational Site, Jinan
GSK Investigational Site, Qingdao
GSK Investigational Site, Tianjin
GSK Investigational Site, Tianjin
GSK Investigational Site, Hangzhou
GSK Investigational Site, Hangzhou
GSK Investigational Site, Wenzhou
GSK Investigational Site, Fuzhou
GSK Investigational Site, Changsha
GSK Investigational Site, Hengyang
GSK Investigational Site, Wuhan
GSK Investigational Site, Zhengzhou
GSK Investigational Site, Guangzhou
GSK Investigational Site, Guangzhou
GSK Investigational Site, Guangzhou
GSK Investigational Site, Guangzhou
GSK Investigational Site, Guangzhou
GSK Investigational Site, Shenzhen
GSK Investigational Site, Zhanjiang
GSK Investigational Site, Guiyang
GSK Investigational Site, Chengdu
GSK Investigational Site, Yinchuan
GSK Investigational Site, Ürümqi
GSK Investigational Site, Shijiazhuang
GSK Investigational Site, Hohhot
GSK Investigational Site, Hohhot
GSK Investigational Site, Taiyuan
Lead Sponsor
GlaxoSmithKline
INDUSTRY